scholarly journals PUK22 A RETROSPECTIVE COHORT STUDY ON CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND DISEASE OUTCOMES IN CHRONIC KIDNEY DISEASE IN PATIENTS WITH DIABETES USING A JAPANESE CLAIMS DATABASE

2019 ◽  
Vol 22 ◽  
pp. S917
Author(s):  
T. Yamazaki ◽  
N. Yoshihara ◽  
J. Yi ◽  
Y. Tanimura ◽  
B. Crawford
2020 ◽  
Author(s):  
Toru Yamazaki ◽  
Nariaki Yoshihara ◽  
Jingbo Yi ◽  
Yoko Tanimura ◽  
Crawford Bruce

Abstract Objectives: The primary objective of this study was to characterize the clinical characteristics, treatment patterns, and clinical outcomes of chronic kidney disease (CKD) patients with diabetes, using a Japanese claims database and focusing on the use of mineralocorticoid receptor antagonists (MRAs) in this population in the real-world setting.Methods: This retrospective cohort study used the Medical Data Vision database, a large, electronic health records-based claims database in Japan. The observation period was a maximum of 8 years (from 1st April 2008 to 31st August 2016). The inclusion criteria were a claim with a diagnosis of diabetes (ICD-10: E10-E14), eGFR less than 60 mL/min/1.73 m2 at the index date, and use of any antiglycemic medications within 6 months prior to the index date or during the index month. Patients who had a claim for an MRA drug after the index date were identified as the MRA subcohort. This exploratory study investigated the burden of disease in patients with CKD and diabetes, including demographics, treatments, safety, and time-to-event analysis for renal and cardiovascular-related endpoints.Results: A total of 19,582 patients were included in the analysis, and 2,295 MRA patients were included in the subcohort. Renin-angiotensin-aldosterone system inhibitors were used at baseline by 52.3% in the overall cohort and 58.8% in the MRA subcohort. Cumulative incidences of hyperkalemia were 5.19% in the overall cohort and 7.63% in the MRA subcohort. Cox models showed that the 30–44 mL/min/1.73 m2 eGFR group had a significantly higher hazard of composite cardiovascular outcomes compared to the 45–59 mL/min/1.73 m2 group (HR, 1.22; 95% CI, 1.09–1.36).Conclusion: There are residual risks for hyperkalemia and renal and cardiovascular-related events in diabetic patients with CKD in the real-world setting in Japan, even after starting treatment with steroidal MRA drugs. The unmet needs and burden of disease should be considered in future treatments for CKD patients with diabetes.


BMJ Open ◽  
2018 ◽  
Vol 8 (4) ◽  
pp. e018928 ◽  
Author(s):  
Soo Kyoung Kim ◽  
Ji Cheol Bae ◽  
Jong-Ha Baek ◽  
Kyu Yeon Hur ◽  
Moon-Kyu Lee ◽  
...  

2020 ◽  
Vol 95 (1) ◽  
pp. 90-100 ◽  
Author(s):  
Reid H. Whitlock ◽  
Ingrid Hougen ◽  
Paul Komenda ◽  
Claudio Rigatto ◽  
Kristin K. Clemens ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document